Piramal’s Healthcare unit will invest $2.5 million at its FDA-approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites from clinical phase to commercial grade. The expansion will provide two commercial grade ADC suites at the facility, while retaining clinical phase manufacturing capacity in other suites on site. Piramal also plans to expand its Proof of Concept (POC) offering at the site for pharma companies looking to demonstrate antibody and/or t...